Objective The global Biologic drug [including Vaccines] market exceeds €500 bn with an annual growth of 8%. Biopharmaceutical companies need to be able to produce these new biologic drugs faster and cheaper to meet the needs of patients, regulators and the governments and insurance companies who are paying for these high cost therapies. Valitacell is an Irish SME which currently supplies this market and is a validated supplier to a growing number of market leaders including GE Healthcare & MedImmune. BIOSIM will accelerate the commercialisation of our ChemStress technology platform for this industry. Scientificallythese tests measure a cell’s performance when exposed to small molecule chemicals which simulate the stresses that the cell will experience in the scaled-up manufacturing process. When applied together they can reduce the average Cell LineDevelopment stage of drug manufacture from 16 to 6 months and reduce the average cost from €2.3million to €1.1 million.BIOSIM will support: the demonstration of ChemStress at 4 leading biopharmaceutical manufacturing sites resulting in the generation of a customer endorsed value proposition; productise the ChemStress platform for the Biopharmmaceutical industry; refinement, scale-up and validation of the product manufacture; priming the sales & marketing for product launch..ChemStress will realise €40m of end-user product sales and support 50 jobs in the 5 years following the project. ChemStress will provide EU Biomanufacturers with the opportunity to maintain their leadership position byimplementing this disruptive innovation and realizing cost reductions. ChemStress will reduce the cost of biological drugs through lower manufacturing costs so enabling EU governments to provide these drugs to EU citizens at a lower cost. Fields of science engineering and technologymechanical engineeringmanufacturing engineeringnatural sciencescomputer and information sciencessoftwareengineering and technologyenvironmental biotechnologybioremediationbioreactorssocial scienceseconomics and businesseconomicsproduction economicsproductivitymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-2-2016-2017 Funding Scheme SME-2 - SME instrument phase 2 Coordinator VALITACELL LTD Net EU contribution € 2 029 325,00 Address FOSTERS AVE. - MOUNT MERRION, BLACKROCK V94 DUBLIN 2 Ireland See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Ireland Southern Mid-West Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 2 029 325,00
